Financial statements of GlaxoSmithKline plc prepared under UK GAAP Expenditure Notes to the company balance sheet UK GAAP Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms.
Provision is A Presentation of the financial statements made when an obligation exists for a future liability in respect of a Description of business past event and where the amount of the obligation can be reliably GlaxoSmithKline plc is the parent company of GSK, a major global estimated.
healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical Investments in subsidiary companies products, including vaccines, over-the-counter OTC medicines Investments in subsidiary companies are held at cost less any and health-related consumer products.
Preparation of financial statements Impairment of investments The financial statements, which are prepared on a going concern The carrying value of investments are reviewed for impairment basis, are drawn up in accordance with UK Generally Accepted when there is an indication that the investment might be impaired.
Accounting Practice UK GAAP and with UK accounting Any provision resulting from an impairment review is charged to presentation as at 31 December 2013, with comparative figures as the income statement in the year concerned.
Where appropriate, comparative figures are reclassified to ensure a consistent presentation with current year Share based payments information.
The issuance by the company to its subsidiaries of a grant over As permitted by section 408 of the Companies Act 2006, the profit the companys shares, represents additional capital contributions and loss account of the company is not presented in this Annual by the company in its subsidiaries.
An additional investment in Report.
subsidiaries results in a corresponding increase in shareholders equity.
The additional capital contribution is based on the fair value of The company is included in the Group accounts of GlaxoSmithKline the grant issued, allocated over the underlying grants vesting period.
plc, which are publicly available.
Advantage has been taken of the exemption provided by FRS 1 Cash flow statements revised 1996 Taxation not to prepare a cash flow statement and of the exemption provided Current tax is provided at the amounts expected to be paid applying by FRS 8 Related party disclosures not to disclose any related party tax rates that have been enacted or substantially enacted by the transactions within the Group.
Accounting convention and standards The company accounts for taxation which is deferred or accelerated The balance sheet has been prepared using the historical cost by reason of timing differences which have originated but not convention and complies with applicable UK accounting standards.
reversed by the balance sheet date.
Deferred tax assets are only recognised to the extent that they are considered recoverable against Accounting principles and policies future taxable profits.
The preparation of the balance sheet in conformity with generally Deferred tax is measured at the average tax rates that are expected accepted accounting principles requires management to make to apply in the periods in which the timing differences are expected estimates and assumptions that affect the reported amounts of to reverse.
Deferred tax liabilities and assets are not discounted.
assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet.
Actual amounts could Financial guarantees differ from those estimates.
Liabilities relating to guarantees issued by the company on behalf of The balance sheet has been prepared in accordance with the its subsidiaries are initially recognised at fair value and amortised over companys accounting policies approved by the Board and described the life of the guarantee.
C O perating profit B Accounting policies A fee of 10,299 2012 10,132 relating to the audit of the Foreign currency transactions company has been charged in operating profit.
Foreign currency transactions are recorded at the exchange rate D Dividends ruling on the date of transaction, or at the forward rate if hedged by a forward exchange contract.
Foreign currency assets and liabilities are The directors declared four interim dividends resulting in a dividend translated at rates of exchange ruling at the balance sheet date, or at for the year of 78 pence, a 4 pence increase on the dividend for the forward rate.
For further details, see Note 16 to the Group financial.
Dividends paid and received Dividends paid and received are included in the accounts in the period in which the related dividends are actually paid or received.
214 GSK Annual Report 2013 Notes to the company balance sheet UK GAAP continued E Fixed assets investments 2013 2012 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,139 1,137 19,691 19,689 F Debtors 2013 2012 m m Amounts due within one year: UK Corporation tax recoverable 203 206 Amounts owed by Group undertakings 2,761 7,319 2,964 7,525 Amounts due after more than one year: Amounts owed by Group undertakings 394 347 3,358 7,872 G Creditors 2013 2012 m m Amounts due within one year: Bank overdraft 10 10 Amounts owed to Group undertakings 61 Other creditors 460 396 531 406 The company has guaranteed debt issued by one of its subsidiary companies for which it receives an annual fee from the subsidiary.
In aggregate, the company has outstanding guarantees over $10.5 billion of debt instruments.
The amounts due from the subsidiary companies in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within debtors see Note F. GSK Annual Report 2013 215 Financial statements of GlaxoSmithKline plc prepared under UK GAAP Notes to the company balance sheet UK GAAP continued H Share capital and share premium account Share Ordinary Shares of 25p each premium Number m m Share capital authorised At 31 December 2012 10,000,000,000 2,500 At 31 December 2013 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2012 5,550,203,098 1,387 1,673 Issued under employee share schemes 28,045,821 7 349 Share capital cancelled 180,652,950 45 At 31 December 2012 5,397,595,969 1,349 2,022 Issued under employee share schemes 44,610,727 12 573 Share capital cancelled 100,000,000 25 At 31 December 2013 5,342,206,696 1,336 2,595 31 December 31 December 2013 2012 000 000 Number of shares issuable under outstanding options 91,303 114,985 Number of unissued shares not under option 4,566,351 4,487,419 At 31 December 2013, of the issued share capital, 63,613,528 shares were held in the ESOP Trusts, 487,433,663 shares were held as Treasury shares and 4,791,159,505 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 42, Employee share schemes.
A total of 92 million shares were purchased by the company during 2013 at a cost of 1,504 million and 100 million shares were cancelled.
The company expects to make further share repurchases of 12 billion during 2014.
The exact amount and timing of further purchases and whether the shares will be held as Treasury shares or be cancelled will be determined by the company and is dependent on market conditions and other factors.
No shares were purchased in the period 1 January 2014 to 5 February 2014.
I Reserves Other Profit and reserves loss account Total m m m At 1 January 2012 1,339 18,689 20,028 Profit attributable to shareholders 10,019 10,019 Dividends to shareholders 3,814 3,814 Shares purchased and cancelled or held as Treasury share 45 2,493 2,448 Capital contribution relating to share based payments 9 9 At 31 December 2012 1,393 22,401 23,794 Profit attributable to shareholders 38 38 Dividends to shareholders 3,680 3,680 Shares purchased and cancelled or held as Treasury share 25 1,504 1,479 Capital contribution relating to share based payments 2 2 At 31 December 2013 1,420 17,179 18,599 The loss of GlaxoSmithKline plc for the year was 38 million 2012 10,019 million profit, which after dividends of 3,680 million 2012 3,814 million, gave a retained loss of 3,718 million 2012 6,205 million profit.
After the cost of shares purchased and cancelled or held as Treasury shares of 1,504 million 2012 2,493, the profit and loss account reserve at 31 December 2013 stood at 17,179 million 2012 22,401 million, of which 4,096 million is unrealised 2012 4,096 million.
